Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 470 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 470 shares of Natera stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $391.49, for a total transaction of $184,000.30. Following the completion of the transaction, the chief financial officer directly owned 45,779 shares in the company, valued at $17,922,020.71. This represents a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, November 2nd, Michael Brophy sold 325 shares of Natera stock. The shares were sold at an average price of $399.99, for a total transaction of $129,996.75.
• On Wednesday, October 28th, Michael Brophy sold 1,178 shares of Natera stock. The stock was sold at an average price of $426.46, for a total transaction of $502,369.88.
• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total value of $317,086.00.

Natera Stock Down 7.0%

NTRA opened at $363.76 on Friday. The firm has a market cap of $52.43 billion, a PE ratio of -267.47 and a beta of 1.55. The business has a fifty day simple moving average of $380.81 and a 200-day simple moving average of $269.30. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $793.98 million for the quarter, compared to analyst estimates of $707.54 million. During the same period last year, the firm earned ($0.64) earnings per share. The firm’s revenue for the quarter was up 34.1% on a year-over-year basis. On average, equities research analysts anticipate that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794.0 million, exceeding analyst expectations of about $707.5 million. The result points to continued business growth. Natera third-quarter 2026 results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Neutral Sentiment: Gross margin was 64.7%, nearly unchanged from 64.9% a year earlier, indicating that strong sales growth came with broadly stable margin performance. Natera third-quarter 2026 results
• Neutral Sentiment: Several executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales may attract attention, but their stated purpose and scheduled nature make them less informative about management’s outlook. Natera insider transaction
• Negative Sentiment: Natera reported a quarterly loss of $0.42 per share, wider than analysts’ expected loss of $0.28. The earnings miss likely outweighed the revenue beat and added pressure on the stock. Natera third-quarter 2026 results

Analysts Set New Price Targets

NTRA has been the topic of several recent analyst reports. Piper Sandler boosted their price objective on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Stephens raised their target price on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Roth Capital initiated coverage on shares of Natera in a research report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price on the stock. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $394.31.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. BlackRock Inc. bought a new position in shares of Natera during the 2nd quarter valued at $2,962,770,000. Arrowstreet Capital Limited Partnership boosted its holdings in Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after purchasing an additional 11,793 shares in the last quarter. Maverick Capital Ltd. boosted its holdings in Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after purchasing an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Natera by 10.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after purchasing an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Natera during the second quarter worth $199,960,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.